Sobi

News

After GSK stumble, Pfizer moves forward with RSV vaccine

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position to bring a shot to market

News

EU gives narrower label to Apellis, Sobi's PNH drug

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US.

News

Did AZ scupper Sobi's $8bn private equity buyout?

An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take it back into private ownership has collapsed, with reports suggesting AstraZen

News

scientifically visualization of a coronavirus spike protein

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May.

News

AZ, Sanofi prep filings for one-shot RSV antibody after tria...

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next year for nirsevimab, an antibody designed to prevent respiratory syncytial virus (RSV)

News

NICE backs Sobi's Kineret for rare inflammatory disease

The UK's cost-effectiveness agency NICE has recommended that Sobi's Kineret can be used to treat NHS patients with Still's disease, a rare form of arthritis affecting children and adults.

After GSK stumble, Pfizer moves forward with RSV vaccine

EU gives narrower label to Apellis, Sobi's PNH drug

Did AZ scupper Sobi's $8bn private equity buyout?

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

AZ, Sanofi prep filings for one-shot RSV antibody after tria...

NICE backs Sobi's Kineret for rare inflammatory disease

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Sobi

Editor's Picks